ReviewMolecular cancer therapeutics2010
Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations.
Review in Molecular cancer therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 105 citations in OpenAlex.
- New uses of halofuginone to treat cancer.Journal of pharmaceutical analysis · 2025Review
- Targeting with Structural Analogs of Natural Products the Purine Salvage Pathway inTropical medicine and infectious disease · 2024Article
- Combination Chemotherapy of Multidrug-resistant Early-stage Colon Cancer: Determining Optimal Dose Schedules by High-performance Computer Simulation.Cancer research communications · 2023Article
- A statistical physics approach for disease module detection.Genome research · 2022Article
- Network Pharmacology Approach for Medicinal Plants: Review and Assessment.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Chemical-Genetic Interactions as a Means to Characterize Drug Synergy.Methods in molecular biology (Clifton, N.J.) · 2021Review
- Network Pharmacology-Based Study on the Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2020Article
- Alzheimer's disease master regulators analysis: search for potential molecular targets and drug repositioning candidates.Alzheimer's research & therapy · 2018Article
- Review
- How Can Synergism of Traditional Medicines Benefit from Network Pharmacology?Molecules (Basel, Switzerland) · 2017Review
- Network Pharmacology Studies on the Bioactive Compounds and Action Mechanisms of Natural Products for the Treatment of Diabetes Mellitus: A Review.Frontiers in pharmacology · 2017Review
- Integrated Computational Analysis of Genes Associated with Human Hereditary Insensitivity to Pain. A Drug Repurposing Perspective.Frontiers in molecular neuroscience · 2017Article
- Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1.Oncotarget · 2016Article
- Identifying causal networks linking cancer processes and anti-tumor immunity using Bayesian network inference and metagene constructs.Biotechnology progress · 2016Article
- Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders.Annual review of pharmacology and toxicology · 2016Review
- Novel Holistic Approaches for Overcoming Therapy Resistance in Pancreatic and Colon Cancers.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2016Review
- An integrated network platform for contextual prioritization of drugs and pathways.Molecular bioSystems · 2015Article
- Systematic synergy modeling: understanding drug synergy from a systems biology perspective.BMC systems biology · 2015Article
- Biased random walk model for the prioritization of drug resistance associated proteins.Scientific reports · 2015Article
- Diverse array-designed modes of combination therapies in Fangjiomics.Acta pharmacologica Sinica · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Cancer therapies that target key molecules have not fulfilled expected promises for most common malignancies. Major challenges include the incomplete understanding and validation of these targets in patients, the multiplicity and complexity of genetic and epigenetic changes in the majority of cancers, and the redundancies and cross-talk found in key signaling pathways. Collectively, the uses of single-pathway targeted approaches are not effective therapies for human malignancies. To overcome these barriers, it is important to understand the molecular cross-talk among key signaling pathways and how they may be altered by targeted agents. Innovative approaches are needed, such as understanding the global physiologic environment of target proteins and the effects of modifying them without losing key molecular details. Such strategies will aid the design of novel therapeutics and their combinations against multifaceted diseases, in which efficacious combination therapies will focus on altering multiple pathways rather than single proteins. Integrated network modeling and systems biology have emerged as powerful tools benefiting our understanding of drug mechanisms of action in real time. This review highlights the significance of the network and systems biology-based strategy and presents a proof of concept recently validated in our laboratory using the example of a combination treatment of oxaliplatin and the MDM2 inhibitor MI-219 in genetically complex and incurable pancreatic adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.